The FDA is investigating severe neurological complications and deaths in patients of maternal Venezuelan ancestry following routine anesthesia with sevoflurane. A rare mitochondrial genetic variant appears to be linked to the serious adverse events. The agency is urging healthcare providers working in Venezuela to consider alternatives like IV or regional anesthesia where possible.
The FDA has issued a safety alert after reports of severe neurological complications and deaths in patients of maternal Venezuelan ancestry who underwent routine general anesthesia with sevoflurane, a widely used inhaled anesthetic. Both adult and pediatric patients have been affected, and published scientific studies have linked the cases to a rare mitochondrial genetic variant.
The variant — MT-ND4 m.11232T>C — has been identified in a subset of patients who experienced serious adverse events after sevoflurane exposure. While current cases are tied specifically to sevoflurane, the FDA says the genetic variant raises broader concerns about all volatile anesthetics. The alert was issued with particular urgency given recent earthquakes in Venezuela, as medical teams are mobilizing to provide care in the region.
Key Takeaways:
Why it matters: This alert highlights a rare but potentially fatal gene-drug interaction that could affect a specific ancestral population. As humanitarian medical efforts ramp up in earthquake-affected Venezuela, awareness of this risk is critical for providers on the ground and those treating Venezuelan patients globally.
